Randomized trial · people
SS-31 raised muscle ATP capacity after one dose in older adults
Checked against the paper Randomized trialPublished by PepVault
The takeaway
One elamipretide infusion briefly raised mitochondrial energy capacity in older human muscle, but in this trial that short-lived gain did not make the muscle more resistant to fatigue.
- Kind
- Randomized trial
- Studied in
- People
- Number studied
- 39
- Published
- 2021
- Journal
- PLoS One
What they tested
The team tested whether a single dose of elamipretide could improve how well mitochondria, the energy-making parts of cells, work in the muscle of older adults.
How the study was done
A randomized, double-blind, placebo-controlled trial in 39 healthy adults aged 60 to 85 (46% women), chosen because their mitochondria worked poorly. Each got one 2-hour infusion of elamipretide or placebo (a dummy treatment), and the team measured a hand muscle, the first dorsal interosseous, right after the infusion and again on day 7.

What they found
Right after the infusion, the elamipretide group showed higher ATPmax than the placebo group. ATPmax is the peak rate at which muscle mitochondria make ATP, the cell's energy molecule, during exercise. The difference had P = 0.055 for the absolute change and P = 0.045 for the percent change, and by day 7 the groups no longer differed. Mitochondrial coupling at rest (P/O, how much ATP is made per unit of oxygen used) did not change significantly, and there was no significant effect on fatigue resistance during repeated contractions.
What it doesn’t show
This was one dose in a small group, measured in a single hand muscle of healthy older adults. The boost faded within a week, did not improve fatigue resistance, and the absolute change in ATPmax fell just short of the usual significance cutoff.
The paper
Roshanravan et al. In vivo mitochondrial ATP production is improved in older adult skeletal muscle after a single dose of elamipretide in a randomized trial. PLoS One. 2021.
The compound
More studies on SS-31
- SS-31 (elamipretide) eye drops missed main vision goal in LHON trialRandomized trial · people · 2024
- SS-31: wearable data grouped responders with 100% accuracyRandomized trial · people · 2023
- SS-31: no 12-week benefit, walk gains by 36 weeks open-labelRandomized trial · people · 2021
- SS-31: walk distance rose with dose in 5-day MMPOWER trialRandomized trial · people · 2018
- SS-31: less kidney hypoxia after renal artery stenting in pilotRandomized trial · people · 2017
- SS-31 did not significantly cut infarct size in EMBRACE STEMIRandomized trial · people · 2016
- Every study on SS-31
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.